All Stories

  1. cyp2c9

    Article • Pharmacogenomics, November 2016, Future Medicine

    Pedro Dorado

  2. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy

    Article • The Pharmacogenomics Journal, June 2015, Nature

    Pedro Dorado

  3. Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem

    Article • Pharmacogenomics, May 2015, Future Medicine

    Pedro Dorado

  4. CYP2D6 Polymorphism and Mental and Personality Disorders in Suicide Attempters

    Article • Journal of Personality Disorders, December 2014, Guilford Publications

    Pedro Dorado

  5. CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas

    Article • Pharmacogenomics, November 2014, Future Medicine

    Pedro Dorado

  6. Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers

    Article • Pharmacogenomics, August 2014, Future Medicine

    Pedro Dorado

  7. CYP2D6 ethnic variability in Hispanics

    Article • February 2014, Future Medicine

    Pedro Dorado

  8. Research Highlights: Novel CYP2C9 genetic polymorphisms and assessment of their impact on hydroxylation capacity

    Article • Pharmacogenomics, February 2014, Future Medicine

    Pedro Dorado

  9. CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers

    Article • Pharmacogenomics, December 2013, Future Medicine

    Pedro Dorado

  10. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment

    Article • Pharmacogenetics and Genomics, November 2013, Wolters Kluwer Health

    Pedro Dorado

  11. Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain

    Article • The Pharmacogenomics Journal, August 2013, Nature

    Pedro Dorado

  12. PP148—Influence of CYP2C9 IVS8-109A>T Polymorphism on Losartan Oxidation in Healthy Ecuadorians

    Article • Clinical Therapeutics, August 2013, Elsevier

    Pedro Dorado

  13. PP157—CYP2C9 Allele Frequencies Among Three Costa Rican Ethnic Groups Compared With Hispanic Populations

    Article • Clinical Therapeutics, August 2013, Elsevier

    Pedro Dorado

  14. Research Highlights

    Article • Pharmacogenomics, April 2013, Future Medicine

    Pedro Dorado

  15. CYP2D6 Polymorphism and Mental and Personality Disorders in Suicide Attempters

    Article • Journal of Personality Disorders, February 2013, Guilford Publications

    Pedro Dorado

  16. Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico

    Article • The Pharmacogenomics Journal, January 2013, Nature

    Pedro Dorado

  17. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

    Article • Molecular Psychiatry, December 2012, Nature

    Pedro Dorado

  18. Eating Disorder Symptoms and CYP2D6 Variation in Cuban Healthy Females: A Report from the Ibero-American Network of Pharmacogenetics

    Article • Current Pharmacogenomics and Personalized Medicine, November 2012, Bentham Science Publishers

    Pedro Dorado

  19. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender

    Article • Pharmacogenomics, November 2012, Future Medicine

    Pedro Dorado

  20. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

    Article • Molecular Psychiatry, June 2012, Nature

    Pedro Dorado

  21. Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6

    Article • The Pharmacogenomics Journal, June 2012, Nature

    Pedro Dorado

  22. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms

    Article • The Pharmacogenomics Journal, May 2012, Nature

    Pedro Dorado

  23. CYP2D6 and the severity of suicide attempts

    Article • Pharmacogenomics, January 2012, Future Medicine

    Pedro Dorado

  24. Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes

    Article • Drug Metabolism and Drug Interactions, January 2012, De Gruyter

    Pedro Dorado

  25. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population

    Article • European Journal of Clinical Pharmacology, November 2011, Springer Science + Business Media

    Pedro Dorado

  26. Research Highlights

    Article • Pharmacogenomics, March 2011, Future Medicine

    Pedro Dorado

  27. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders

    Article • Molecular Psychiatry, February 2011, Nature

    Pedro Dorado, Fernando Fernandez-Aranda

  28. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

    Article • The Pharmacogenomics Journal, December 2010, Nature

    Pedro Dorado

  29. CYP2D6 polymorphism in patients with eating disorders

    Article • The Pharmacogenomics Journal, September 2010, Nature

    Pedro Dorado, Fernando Fernandez-Aranda

  30. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards

    Article • The Pharmacogenomics Journal, May 2010, Nature

    Pedro Dorado

  31. Pharmacogenomics and Personality: Role of CYP2D6 and Implications for Psychopathology

    Article • January 2010, Karger Publishers

    Pedro Dorado

  32. Influence of CYP2D6 Deletion, Multiplication, –1584C→G, 31G→A and 2988G→A Gene Polymorphisms on Dextromethorphan Metabolism among Mexican Tepehuanos and Mestizos

    Article • Pharmacology, January 2010, Karger Publishers

    Pedro Dorado

  33. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers

    Article • Pharmacogenomics, July 2009, Future Medicine

    Pedro Dorado

  34. Relevance of CYP2D6-1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients

    Article • Pharmacogenomics, July 2009, Future Medicine

    Pedro Dorado

  35. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

    Article • Pharmacogenomics, January 2009, Future Medicine

    Pedro Dorado

  36. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers

    Article • Pharmacogenomics, July 2008, Future Medicine

    Pedro Dorado

  37. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits

    Article • Pharmacogenomics, November 2007, Future Medicine

    Pedro Dorado

  38. Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele

    Article • Fundamental and Clinical Pharmacology, August 2007, Wiley

    Pedro Dorado

  39. Estudio farmacogenético del polimorfismo metabólico de la debrisoquina (CYP2D6) en la población cubana en relación con la española

    Article • Medicina Clínica, May 2007, Elsevier

    Pedro Dorado

  40. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients

    Article • The Pharmacogenomics Journal, February 2007, Nature

    Pedro Dorado

  41. Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism

    Article • Expert Opinion on Drug Metabolism & Toxicology, February 2007, Informa Healthcare

    Pedro Dorado

  42. Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs

    Article • Current Drug Targets, December 2006, Bentham Science Publishers

    Pedro Dorado

  43. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use

    Article • BioTechniques, October 2005, Future Science

    Pedro Dorado

  44. CYP2C9 and clinical response to antidepressant drugs in Mexican-Americans

    Article • Clinical Pharmacology & Therapeutics, February 2005, Nature

    Pedro Dorado

  45. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2005, De Gruyter

    Pedro Dorado

  46. QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations

    Article • Journal of Psychopharmacology, June 2004, SAGE Publications

    Pedro Dorado

  47. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions

    Article • European Journal of Clinical Pharmacology, February 2004, Springer Science + Business Media

    Pedro Dorado

  48. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards

    Article • The Pharmacogenomics Journal, January 2004, Nature

    Pedro Dorado

  49. CYP2C9 genotypes and diclofenac

    Article • European Journal of Clinical Pharmacology, July 2003, Springer Science + Business Media

    Pedro Dorado

  50. Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios

    Article • Journal of Chromatography B, June 2003, Elsevier

    Pedro Dorado

  51. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

    Article • European Journal of Clinical Pharmacology, March 2003, Springer Science + Business Media

    Pedro Dorado

  52. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions

    Article • Journal of Chromatography B, January 2003, Elsevier

    Pedro Dorado

  53. CYP2C9 gene and susceptibility to major depressive disorder

    Article • The Pharmacogenomics Journal, January 2003, Nature

    Pedro Dorado

  54. Relationship between Risperidone and 9-hydroxy-risperidone Plasma Concentrations and CYP2D6 Enzyme Activity in Psychiatric Patients

    Article • Pharmacopsychiatry, November 2002, Thieme Publishing Group

    Pedro Dorado

  55. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients

    Article • Journal of Psychopharmacology, July 2002, SAGE Publications

    Pedro Dorado

  56. losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

    Article • Clinical Pharmacology & Therapeutics, January 2002, Nature

    Pedro Dorado

  57. Effect of Thioridazine Dosage on the Debrisoquine Hydroxylation Phenotype in Psychiatric Patients With Different CYP2D6 Genotypes

    Article • Therapeutic Drug Monitoring, December 2001, Wolters Kluwer Health

    Pedro Dorado